295 related articles for article (PubMed ID: 33591799)
1. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
[TBL] [Abstract][Full Text] [Related]
2. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?
Zeng Z; Li Z; Luo S; Huang L; Liang Z; Zheng X; Li W; Xiong L; Liu H; Kang L
J Gastroenterol Hepatol; 2024 May; 39(5):858-867. PubMed ID: 38225773
[TBL] [Abstract][Full Text] [Related]
3. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.
Chen M; Ma Y; Song YW; Huang J; Gao YH; Zheng J; He F
Cancer Med; 2023 Nov; 12(21):20523-20537. PubMed ID: 37864414
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
6. Pretreatment MRI-detected extramural venous invasion as a prognostic and predictive biomarker for neoadjuvant chemoradiotherapy in non-metastatic rectal cancer: a propensity score matched analysis.
Yang SY; Bae H; Seo N; Han K; Han YD; Cho MS; Hur H; Min BS; Kim NK; Lee KY; Lim JS
Eur Radiol; 2024 Jun; 34(6):3686-3698. PubMed ID: 37994967
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
[TBL] [Abstract][Full Text] [Related]
8. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
9. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
10. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
11. MRI-detected tumor deposits in cT3 and cT4 rectal cancer following neoadjuvant chemoradiotherapy.
Que YT; Chen Y; Yang XY; Ma YR; Liu YY; Wen ZQ; Lu BL; Wu XH; Zhang ZW; Wu YZ; Yu SP; Yuan JP
Eur Radiol; 2024 May; 34(5):2963-2973. PubMed ID: 37840101
[TBL] [Abstract][Full Text] [Related]
12. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.
Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Junginger T; Hermanek P; Merkel S;
J Am Coll Surg; 2020 Oct; 231(4):413-425.e2. PubMed ID: 32697965
[TBL] [Abstract][Full Text] [Related]
13. Low- Versus High-Risk Rectal Cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy.
Jia XX; Wang Y; Cheng J; Yao X; Yin MJ; Zhou J; Ye YJ
AJR Am J Roentgenol; 2018 Aug; 211(2):327-334. PubMed ID: 29927331
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
15. Preoperative lateral lymph node features and impact on local recurrence after neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: results from a multicentre international cohort study.
Achilli P; Ferrari D; Calini G; Bertoglio CL; Magistro C; Origi M; Carnevali P; Alampi BD; Giusti I; Ferrari G; Calafiore E; Spinelli A; Grass F; Deslarzes P; Hahnloser D; Abdalla S; Larson DW
Colorectal Dis; 2024 Mar; 26(3):466-475. PubMed ID: 38243617
[TBL] [Abstract][Full Text] [Related]
16. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
17. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
18. Implication of MRI Risk Stratification System on the Survival Benefits of Adjuvant Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
Zhao R; Zhao W; Zhu Y; Wan L; Chen S; Zhao Q; Zhao X; Zhang H
Acad Radiol; 2023 Sep; 30 Suppl 1():S164-S175. PubMed ID: 37369619
[TBL] [Abstract][Full Text] [Related]
19. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.
Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M;
JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
